Abstract
Atrial fibrillation (AF) is a worldwide public health problem, with a prevalence of 10% to 15% after 80 years of age. The morbidity and mortality secondary to AF is high. With regard to the outcomes of stroke, the attributable risk of AF increases sharply from 1.5% to 23.5% for ages 50 to 59 years and 80 to 89 years, respectively. AF-related stroke is particularly concerning as it carries a high mortality, with 1 in 4 patients dying within 30 days. This article discusses stroke prevention in elderly patients with AF, including data on the advances in pharmacological therapeutic and agent selection that are used to balance thromboembolic risk with bleeding risk in patients with AF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
